This research is Trending!
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction
Milind Y. DesaiAnjali OwensKathy WolskiJeffrey B. GeskeSara SaberiAndrew WangMark V. SherridPaul CremerNeal K. LakdawalaAlbree Tower‐RaderDavid FerminSrihari S. NaiduNicholas G. SmediraHartzell V. SchaffEllen McErleanChristina SewellYue ZhongKathleen W. WyrwichKathy LamplAmy J. SehnertSteven E. NissenJohn A. Spertus
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceAsk about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“VALOR-HCM supports extended use of mavacamten as a viable long-term therapeutic option for patients with symptomatic obstructive HCM who were referred for SRT. The drug was well tolerated, and sustained freedom from SRT was observed at 128 weeks, with nearly 90% of patients remaining on long-term mavacamten.”
“[Treatment with mavacamten] definitely provides an alternative for medically refractory patients with obstructive HCM, which may obviate the need for SRT in many patients. We however still continue to need long term studies of efficacy and outcomes.”
“So bottom line is they were at the end of the road and the only other option was to have an invasive procedure, so much sicker population compared to the prior studies.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Desai et al. (2024) studied this question.